These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19669311)

  • 41. Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
    Song MN; Hong MZ; Luo DQ; Huang WQ; Min F; Fan RH; Wu WB; Zhang L
    World J Hepatol; 2012 Dec; 4(12):389-93. PubMed ID: 23355917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.
    Kozielewicz D; Halota W; Wietlicka-Piszcz M
    Hepatol Int; 2016 Mar; 10(2):302-9. PubMed ID: 26612013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
    Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
    Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis.
    Wang HL; Lu X; Yang X; Xu N
    Gastroenterol Res Pract; 2016; 2016():3435965. PubMed ID: 27672391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
    Lee YB; Lee JH; Lee DH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6710-6. PubMed ID: 25155601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
    Fasano M; Maggi P; Leone A; Volpe A; Fiore JR; Angarano G; Santantonio TA
    Dig Liver Dis; 2017 May; 49(5):530-534. PubMed ID: 28179096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
    Lee YB; Jung EU; Kim BH; Lee JH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Park SJ; Kim YJ; Park JW; Lee YJ; Kim CM; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2015 Feb; 59(2):972-8. PubMed ID: 25421484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
    Zoulim F; Parvaz P; Marcellin P; Zarski JP; Beaugrand M; Benhamou Y; Bailly F; Maynard M; Trepo C; Trylesinski A; Monchecourt F;
    Liver Int; 2009 Mar; 29(3):420-6. PubMed ID: 18795900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.
    Wu S; Fukai K; Imazeki F; Arai M; Kanda T; Yonemitsu Y; Yokosuka O
    Dig Dis Sci; 2011 Apr; 56(4):1207-14. PubMed ID: 20927588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Sheng YJ; Liu JY; Tong SW; Hu HD; Zhang DZ; Hu P; Ren H
    Virol J; 2011 Aug; 8():393. PubMed ID: 21824397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
    Peters MG; Andersen J; Lynch P; Liu T; Alston-Smith B; Brosgart CL; Jacobson JM; Johnson VA; Pollard RB; Rooney JF; Sherman KE; Swindells S; Polsky B;
    Hepatology; 2006 Nov; 44(5):1110-6. PubMed ID: 17058225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
    Kim BG; Jung SW; Kim EH; Kim JH; Park JH; Sung SJ; Park BR; Kim MH; Kim CJ; Lee BU; Park JH; Jeong ID; Bang SJ; Shin JW; Park NH
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1514-21. PubMed ID: 25973716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.